- Global Blood Therapeutics ( NASDAQ: GBT ) said on Wednesday it had begun the Phase 2 portion of a Phase 2/3 trial of its drug candidate GBT601, to treat sickle cell disease.
- The drug, GBT601, is a sickle hemoglobin (HbS) polymerization inhibitor and works by achieving higher hemoglobin levels and occupancy at a lower dose.
- "It has the potential to improve on the clinical results achieved with Oxbryta at a lower daily dose," said Kim Smith-Whitley, head of research and development of GBT.
- The company's drug, Oxbryta, is FDA approved to treat sickle cell disease.
- The company expects initial data from the trial as well as data from the continuation of GBT601 Phase 1 study to be available before the end of the year.
- The mid-stage portion of the study will enroll up to 60 patients who are 18 to 65 years of age.
For further details see:
GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease